ID

15275

Descripción

Intensity Modulated Radiation Therapy - Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00188513

Link

https://clinicaltrials.gov/show/NCT00188513

Palabras clave

Versiones (1)
  1. 24/5/16 24/5/16 -
Subido en

24 de mayo de 2016

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Prostatic Neoplasms NCT00188513

Inglés

Eligibility Prostatic Neoplasms NCT00188513

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
histologic diagnosis of adenocarcinoma of the prostate within six months of entry
Descripción

adenocarcinoma

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001418
clinical stage t1b, t1c, t2a-c nx mo (see appendix 1 for staging). any gleason score is eligible for entry, but gleason score must be determined.
Descripción

staging

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0027646
UMLS CUI [2]
C3203027
patients with a psa >10.0 and gleason score of 7; or patients with any psa value and gleason score of >8 must have clinically negative lymph nodes as determined by a pelvic ct scan done within 12 weeks of entry. a negative bone scan is required before entry for all patients with gleason score >8, or any patient with a gleason score of 7, and a psa >10.
Descripción

PSA and gleason score

Tipo de datos

boolean

Alias
UMLS CUI [1]
C3203027
UMLS CUI [2]
C0138741
UMLS CUI [3,1]
C0024204
UMLS CUI [3,2]
C1513916
the patient must not have received any cytotoxic anticancer therapy. previous or concurrent hormonal therapy for local disease is acceptable.
Descripción

cytotoxic anticancer therapy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0677881
UMLS CUI [2]
C0279025
ecog performance status of 1 or less
Descripción

ecog performance status

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1520224
age 80 years old or less
Descripción

age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
serum psa <25 ng/ml within 4 weeks of study entry
Descripción

serum psa

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2123607
informed consent
Descripción

informed consent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients with history of inflammatory bowel disease or other contraindication to radical radiation therapy
Descripción

inflammatory bowel disease

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021390
UMLS CUI [2,1]
C1522449
UMLS CUI [2,2]
C1301624
patients with prior colorectal surgery
Descripción

colorectal surgery

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0543467
any prior pelvic radiotherapy. any prior turp done <12 weeks from study entry.
Descripción

pelvic radiotherapy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0436276
any previous cytotoxic chemotherapy
Descripción

cytotoxic chemotherapy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0677881
patients with prior malignancy except non-melanoma skin carcinoma within 5 years of the diagnosis of prostate cancer
Descripción

prior malignancy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0006826
Volver a la parte superior de la página

Similar models

Eligibility Prostatic Neoplasms NCT00188513

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
adenocarcinoma
Item
histologic diagnosis of adenocarcinoma of the prostate within six months of entry
boolean
C0001418 (UMLS CUI [1])
staging
Item
clinical stage t1b, t1c, t2a-c nx mo (see appendix 1 for staging). any gleason score is eligible for entry, but gleason score must be determined.
boolean
C0027646 (UMLS CUI [1])
C3203027 (UMLS CUI [2])
PSA and gleason score
Item
patients with a psa >10.0 and gleason score of 7; or patients with any psa value and gleason score of >8 must have clinically negative lymph nodes as determined by a pelvic ct scan done within 12 weeks of entry. a negative bone scan is required before entry for all patients with gleason score >8, or any patient with a gleason score of 7, and a psa >10.
boolean
C3203027 (UMLS CUI [1])
C0138741 (UMLS CUI [2])
C0024204 (UMLS CUI [3,1])
C1513916 (UMLS CUI [3,2])
cytotoxic anticancer therapy
Item
the patient must not have received any cytotoxic anticancer therapy. previous or concurrent hormonal therapy for local disease is acceptable.
boolean
C0677881 (UMLS CUI [1])
C0279025 (UMLS CUI [2])
ecog performance status
Item
ecog performance status of 1 or less
boolean
C1520224 (UMLS CUI [1])
age
Item
age 80 years old or less
boolean
C0001779 (UMLS CUI [1])
serum psa
Item
serum psa <25 ng/ml within 4 weeks of study entry
boolean
C2123607 (UMLS CUI [1])
informed consent
Item
informed consent
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
inflammatory bowel disease
Item
patients with history of inflammatory bowel disease or other contraindication to radical radiation therapy
boolean
C0021390 (UMLS CUI [1])
C1522449 (UMLS CUI [2,1])
C1301624 (UMLS CUI [2,2])
colorectal surgery
Item
patients with prior colorectal surgery
boolean
C0543467 (UMLS CUI [1])
pelvic radiotherapy
Item
any prior pelvic radiotherapy. any prior turp done <12 weeks from study entry.
boolean
C0436276 (UMLS CUI [1])
cytotoxic chemotherapy
Item
any previous cytotoxic chemotherapy
boolean
C0677881 (UMLS CUI [1])
prior malignancy
Item
patients with prior malignancy except non-melanoma skin carcinoma within 5 years of the diagnosis of prostate cancer
boolean
C0006826 (UMLS CUI [1])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial